Navigation Links
Androgen Production Continues in Prostate Cancer Tumors
Date:6/3/2008

Growths are able to maintain significant testosterone levels despite therapy, study finds

TUESDAY, June 3 (HealthDay News) -- U.S. researchers have uncovered new information about how metastatic prostate cancer becomes resistant to androgen-deprivation therapy, which suppresses circulating testosterone, the hormone that promotes prostate cancer growth.

Androgen therapy, which involves the use of surgical castration or medical castration with testosterone-blocking drugs, does extend survival time for patients, but it isn't a cure. Eventually, the cancer becomes resistant to androgen deprivation and continues to grow.

"We found that despite the suppression of circulating androgen levels to very low or castrate levels, metastatic prostate tumors are themselves able to maintain significant levels of testosterone, which fuels the growth of the cancer," Dr. Elahe Mostaghel, a clinical research association at Seattle's Fred Hutchinson Cancer Research Center, said in a prepared statement.

Mostaghel and colleagues found that testosterone levels in metastatic prostate tumors (cancer that's spread from the prostate to other parts of the body) from castrate men who'd just died were four times higher than in benign and cancerous prostate tissue in men with normal circulating androgen levels.

They also discovered that metastatic prostate tumor tissue contains the genetic information needed to make the proteins that produce testosterone and other androgen hormones.

"We not only found that metastatic tumor tissues have high enough androgen levels within them to support continued growth of the tumor cells, but also a critically important reason behind why those androgens are there -- the discovery that the gene pathways for synthesizing androgens from cholesterol appear to be present in the distant tumor sites. This finding will allow us to start honing in on the specific source of those androgens and how we can eliminate them," Mostaghel said.

"As we develop new drug targets, we will need to focus on enzymes that seem to be active in the tumor itself. This offers a new way of looking at hormone suppression. In addition to systemic suppression, it suggests we also need to target hormone suppression much more specifically, inside the tumor itself."

The study was published in the June 1 issue of Cancer Research.

More information

The National Cancer Institute has more about prostate cancer treatment.



-- Robert Preidt



SOURCE: Fred Hutchinson Cancer Research Center, news release, June 1, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. How advanced prostate cancer becomes resistant to androgen-deprivation therapy
2. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
3. Golden Rainbow Takes a Musical Journey for Its 22nd Annual Ribbon of Life Production Show
4. JMR Electronics BlueStor(TM) Storage Array Empowers HoneySheds Post Production Process
5. Dutch Authorize Manufacture of Vaccinogens New Cancer Vaccine; License Clears Path to European Production, Final FDA Trial
6. Epitomics receives ISO 9001 certification for the production of Rabbit Monoclonal Antibodies.
7. Pfizer Partners with REvolution Computing to Improve Medicine Production Pipeline
8. Vystar Corporation and Revertex Malaysia Sign Vytex(TM) NRL Production Contract
9. Disturbed regulation of insulin production
10. European Society of Human Reproduction & Embryology 24th annual meeting
11. Worlds Lightest, Rigid, Folding Frame Wheelchair now in Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud ... and unique items from across the nation, this holiday-themed event will raise funds and ... the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains ... possible to save lost souls in the Philippines. “The Journey: From the Mountains to ... dedicated teacher of the Bible. She has taught all ages and currently teaches a ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... FRISCO, Texas , Oct. 11, 2017 /PRNewswire/ ... healthcare services, has amplified its effort during National ... patients about hereditary cancer risks. ... Journal of Clinical Oncology calculated that more than ... to have inherited mutations in BRCA1 or BRCA2 and ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
Breaking Medicine Technology: